Eli Lilly and Company’s Olumiant (baricitinib) has been recommended for approval in Europe for adolescents with severe alopecia areata (AA). Incyte first discovered the Janus kinase (JAK) inhibitor, then licensed it to Lilly. What Alopecia Areata Is AA is an autoimmune disease that attacks hair follicles, causing hair loss potentially anywhere on the body. However, it usually primarily affects the head and face. Hair falls out in small, round (approximately quarter-sized) patches. Early...